Share on LinkedInShare on LinkedIn

ARTICLE · 05 DECEMBER 2025

European Commission Secures "Pay For Delay" Victory In Top EU Court Ruling

A&O Shearman
A&O Shearman
Contributor

A&O Shearman

Introducing A&O Shearman Unparalleled global depth for a changing world. Today more than ever,...

View firm profile
Explore more from A&O Shearman

The Court of Justice of the European Union (CJEU) has upheld a General Court (GC) judgment that sided with the European Commission (EC)'s decision to fine Teva and Cephalon for a "pay for delay" pharmaceutical patent settlement agreement.

European UnionAntitrust/Competition Law

The Court of Justice of the European Union (CJEU) has upheld a General Court (GC) judgment that sided with the European Commission (EC)'s decision to fine Teva and Cephalon for a "pay for delay" pharmaceutical patent settlement agreement. The judgment reinforces the EC's established approach to assessing whether patent settlement agreements—and related commercial side agreements—may amount to an illegal "pay for delay" arrangement under EU antitrust rules.

Third (and final) decision in four years

The EC first imposed fines (EUR60.5 million in total) on Teva and Cephalon (now Teva's subsidiary) in 2020. It found that the companies had agreed to delay the market entry of a generic version of Cephalon's sleep disorder medicine Modafinil, in exchange for cash payments and commercial side deals.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from